“OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study”, J of Skin, vol. 1, no. 3.1, p. s82, Oct. 2017, doi: 10.25251/skin.1.supp.81.